202 related articles for article (PubMed ID: 23903893)
1. Polymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammation.
Washburn NR; Prata JE; Friedrich EE; Ramadan MH; Elder AN; Sun LT
Biomatter; 2013; 3(3):. PubMed ID: 23903893
[TBL] [Abstract][Full Text] [Related]
2. Tip-Loaded Dissolvable Microneedle Arrays Effectively Deliver Polymer-Conjugated Antibody Inhibitors of Tumor-Necrosis-Factor-Alpha Into Human Skin.
Korkmaz E; Friedrich EE; Ramadan MH; Erdos G; Mathers AR; Ozdoganlar OB; Washburn NR; Falo LD
J Pharm Sci; 2016 Nov; 105(11):3453-3457. PubMed ID: 27544434
[TBL] [Abstract][Full Text] [Related]
3. Effects of hyaluronic acid conjugation on anti-TNF-α inhibition of inflammation in burns.
Friedrich EE; Sun LT; Natesan S; Zamora DO; Christy RJ; Washburn NR
J Biomed Mater Res A; 2014 May; 102(5):1527-36. PubMed ID: 23765644
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of antitumor necrosis factor-α through conjugation to hyaluronic acid: dosing strategies and early healing effects in a rat burn model.
Friedrich EE; Azofiefa A; Fisch E; Washburn NR
J Burn Care Res; 2015; 36(2):e90-e101. PubMed ID: 25526179
[TBL] [Abstract][Full Text] [Related]
5. Cytokine binding by polysaccharide-antibody conjugates.
Sun LT; Buchholz KS; Lotze MT; Washburn NR
Mol Pharm; 2010 Oct; 7(5):1769-77. PubMed ID: 20726535
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis.
Moreland LW
Cleve Clin J Med; 1999 Jun; 66(6):367-74. PubMed ID: 10375846
[TBL] [Abstract][Full Text] [Related]
7. TNFalpha blockade in human diseases: mechanisms and future directions.
Wong M; Ziring D; Korin Y; Desai S; Kim S; Lin J; Gjertson D; Braun J; Reed E; Singh RR
Clin Immunol; 2008 Feb; 126(2):121-36. PubMed ID: 17916444
[TBL] [Abstract][Full Text] [Related]
8. Transport patterns of anti-TNF-α in burn wounds: Therapeutic implications of hyaluronic acid conjugation.
Friedrich EE; Washburn NR
Biomaterials; 2017 Jan; 114():10-22. PubMed ID: 27837681
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.
Liang S; Dai J; Hou S; Su L; Zhang D; Guo H; Hu S; Wang H; Rao Z; Guo Y; Lou Z
J Biol Chem; 2013 May; 288(19):13799-807. PubMed ID: 23504311
[TBL] [Abstract][Full Text] [Related]
10. Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates.
Sun LT; Bencherif SA; Gilbert TW; Farkas AM; Lotze MT; Washburn NR
Wound Repair Regen; 2010; 18(3):302-10. PubMed ID: 20412551
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.
Hu S; Liang S; Guo H; Zhang D; Li H; Wang X; Yang W; Qian W; Hou S; Wang H; Guo Y; Lou Z
J Biol Chem; 2013 Sep; 288(38):27059-27067. PubMed ID: 23943614
[TBL] [Abstract][Full Text] [Related]
13. Transcending conventional therapies: the role of biologic and other novel therapies.
Sandborn WJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
[TBL] [Abstract][Full Text] [Related]
14. Reduction of burn progression with topical delivery of (antitumor necrosis factor-α)-hyaluronic acid conjugates.
Sun LT; Friedrich E; Heuslein JL; Pferdehirt RE; Dangelo NM; Natesan S; Christy RJ; Washburn NR
Wound Repair Regen; 2012; 20(4):563-72. PubMed ID: 22712482
[TBL] [Abstract][Full Text] [Related]
15. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
16. Design principles for cytokine-neutralizing gels: Cross-linking effects.
Sun LT; Bencherif SA; Gilbert TW; Lotze MT; Washburn NR
Acta Biomater; 2010 Dec; 6(12):4708-15. PubMed ID: 20601239
[TBL] [Abstract][Full Text] [Related]
17. TNFalpha as therapeutic target: new drugs, more applications.
Reimold AM
Curr Drug Targets Inflamm Allergy; 2002 Dec; 1(4):377-92. PubMed ID: 14561184
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for tumor necrosis factor-alpha inhibitors and especially thalidomide in dermatology?
Moschella SL
Skinmed; 2005; 4(1):19-30; quiz 31-2. PubMed ID: 15654161
[TBL] [Abstract][Full Text] [Related]
19. TNFalpha blockade in human diseases: an overview of efficacy and safety.
Lin J; Ziring D; Desai S; Kim S; Wong M; Korin Y; Braun J; Reed E; Gjertson D; Singh RR
Clin Immunol; 2008 Jan; 126(1):13-30. PubMed ID: 17916445
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.
Cordero-Coma M; Yilmaz T; Onal S
Ocul Immunol Inflamm; 2013; 21(1):19-27. PubMed ID: 23323577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
